A Phase 1 interventional study of LY900014-U200 and LY900014-U100 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-01.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study involves a comparison of a LY900014 U-200 formulation with a LY900014 U-100 formulation. LY900014 is a type of fast acting insulin. Study participants will be administered LY900014 U-100 two times and LY900014 U-200 two times, over 4 study periods, by injection under the skin. Blood samples will be taken to compare how the body handles the study drugs and how they affect the blood sugar levels. Side effects and tolerability will be documented. The study will last about 4 weeks, not including screening and follow up. Screening is required within 28 days prior to the start of the study and follow up is required at least 2 weeks after the last dose of study drug.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods
Drug: LY900014-U200
Single SC dose of 15 U LY900014 U-100 in two of four study periods
Drug: LY900014-U100
Administered SC
Also known as: Ultra-Rapid Lispro
Administered SC
Also known as: Ultra-Rapid Lispro
Pharmacokinetics (PK): Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours (AUC[0-10])
Insulin Lispro AUC From Time Zero to 10 hours post dose (AUC\[0-10h\])
Time frame: Predose, 5 minutes (mn), 10mn, 15mn, 20mn, 25mn, 30mn, 35mn, 40mn, 45 mn, 50mn, 55 mn, 60mn, 70mn,90mn,120mn,150mn,180mn, 240mn,300mn,360mn,320mn, 480mn, 540mn, and 600mn (10 hours)
Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm
Glucodynamics: Gtot is the total glucose infusion over the clamp duration (10 hours) and is used to measure the study drug action over time as measured by the euglycemic clamp (EC) procedure.
Time frame: Predose, every minute from run-in and for the duration of the EC until up to 10 hours postdose
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 12 | 12 | 13 | 12 |
| Received at least 1 dose of study drug | 12 | 12 | 13 | 12 |
| Completed | 12 | 12 | 13 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 12 | 12 | 13 | 12 |
| Completed | 12 | 12 | 13 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 12 | 12 | 13 | 12 |
| Received at least 1 dose of study drug | 12 | 12 | 13 | 12 |
| Completed | 12 | 12 | 13 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 12 | 12 | 13 | 12 |
| Completed | 12 | 11 | 13 | 12 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Personal reason | 0 | 1 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 12 | 11 | 13 | 12 |
| Received at least 1 dose of study drug | 12 | 11 | 13 | 12 |
| Completed | 12 | 11 | 13 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 12 | 11 | 13 | 12 |
| Completed | 12 | 11 | 13 | 11 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 12 | 11 | 13 | 11 |
| Received at least 1 dose of study drug | 12 | 11 | 13 | 11 |
| Completed | 12 | 11 | 13 | 11 |
| Not completed | 0 | 0 | 0 | 0 |
Insulin Lispro AUC From Time Zero to 10 hours post dose (AUC\[0-10h\])
| hours times picomols per milliliter | LY900014-U100 | LY900014-U200 |
|---|---|---|
| Pharmacokinetics (PK): Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours (AUC[0-10]) | 1760 ± 19 | 1550 ± 42 |
Glucodynamics: Gtot is the total glucose infusion over the clamp duration (10 hours) and is used to measure the study drug action over time as measured by the euglycemic clamp (EC) procedure.
| milligrams per kilogram (mg/kg) | LY900014-U100 | LY900014-U200 |
|---|---|---|
| Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm | 1500 ± 47 | 1410 ± 55 |
Collected over Up to 15 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY900014-U100 | 0/49 (0%) | 0/49 (0%) | 32/49 (65.3%) |
| LY900014-U200 | 0/49 (0%) | 0/49 (0%) | 35/49 (71.4%) |
| Event | LY900014-U100 | LY900014-U200 |
|---|---|---|
| Injection site reactionGeneral disorders | 23/49 | 16/49 |
| Infusion site painGeneral disorders | 6/49 | 10/49 |
| Catheter site bruiseGeneral disorders | 6/49 | 6/49 |
| Catheter site swellingGeneral disorders | 6/49 | 2/49 |
| Infusion site bruisingGeneral disorders | 3/49 | 6/49 |
| Infusion site swellingGeneral disorders | 5/49 | 4/49 |
| Catheter site painGeneral disorders | 4/49 | 2/49 |
| PyrexiaGeneral disorders | 3/49 | 2/49 |
| HeadacheNervous system disorders | 3/49 | 1/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/49 | 3/49 |
All randomized participant who received at least 1 dose of study drug.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 39.7 ± 8.2 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 5 |
| Male | 44 |
| Ethnicity (NIH/OMB)(Participants) | Overall |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 49 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 47 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall |
|---|---|
| Singapore | 49 |
| Weight(kilograms (kg)) | Overall |
|---|---|
| Mean | 72.16 ± 10.97 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Mar 2018, 3 months.
Results were first posted in May 2020, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Lispro